Why the study?
Does BN 52021 prevent hematologic changes and reduce blood loss in patients undergoing cardiopulmonary bypass?
Population
28 patients undergoing cardiopulmonary bypass
Comparison
BN 52021 infused intravenously before vascular… vs Placebo infused intravenously before vascular…
Design
RCT
Follow-up
48 hours postoperatively
Authors
Loading...
Does not support BN 52021 use to limit blood loss in cardiopulmonary bypass; confirms lack of benefit from PAF antagonism.
Does BN 52021 prevent hematologic changes and reduce blood loss in patients undergoing cardiopulmonary bypass?
Pretreatment with the PAF receptor antagonist BN 52021 does not protect against cardiopulmonary bypass-induced hematologic changes or reduce blood loss.
Nathan et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: